##common.pageHeaderLogo.altText##

Original article

Vol. 154 No. 11 (2024)

Antipsychotic, benzodiazepine and Z-drug prescriptions in a Swiss hospital network in the Choosing Wisely and COVID-19 eras: a longitudinal study

Cite this as:
Swiss Med Wkly. 2024;154:3409
Published
01.11.2024

Summary

AIMS OF THE STUDY: Physicians frequently prescribe antipsychotics off-label to treat, among others, insomnia and anxiety. The Swiss “smarter medicine – Choosing Wisely” campaign has tried to raise awareness about the risks and to limit benzodiazepine and Z-drug prescriptions. In the Italian-speaking part of Switzerland, our network of public hospitals joined the campaign with the aim of avoiding unnecessary benzodiazepine and Z-drug treatments, with prescription monitoring, benchmarking and educational contributions. Considering the risks of a possible shift towards the prescription of antipsychotics, and aware of the potential role of the COVID-19 pandemic, we decided to analyse the prescription trends of antipsychotics and benzodiazepines/Z-drugs before, during (2016–2017) and after the intervention.

METHODS: For this longitudinal study, we reactivated a continuous monitoring of inpatient benzodiazepine/Z-drug and antipsychotics prescriptions/deprescriptions, paused in 2018 after the end of the internal Choosing Wisely campaign, based on routinely collected observational health data. We screened all demographic, administrative and prescription data of patients admitted to the internal medicine department of the four teaching hospitals (H1-H4) belonging to the EOC (Ente Ospedaliero Cantonale) network, from the fourth quarter of 2014 to the second quarter of 2023.

RESULTS: We analysed 74,659 hospital stays (14,645 / 16,083 / 24,285 / 19,646 at hospitals H1 / H2 / H3 / H4 respectively). The mean (± SD) case mix (a metric that reflects the diversity, complexity and severity of the treated patients) and patient age were 1.08 ± 0.14 and 73 ± 2 years. 10.6% and 12.1% of patients received antipsychotics prior to admission and at discharge respectively (new prescriptions 3.3 ± 0.7%; deprescriptions 13.3 ± 5.2%). New prescriptions showed an upward trend, with +0.20% per year (p <0.001). Patients admitted with ongoing antipsychotics therapy increased 0.36% per year (p <0.001). New benzodiazepine/Z-drug prescriptions showed a 0.20% per year decrease (p = 0.01). Patients admitted with ongoing benzodiazepine/Z-drug therapy decreased 0.32% per year (p <0.001). New antipsychotics prescriptions showed differences between hospitals, with H3 above and H2 below the average.

CONCLUSIONS: The increase in antipsychotics quantitatively matched the decrease in benzodiazepine/Z-drug prescribing, suggesting a shift from one to the other sedative therapy. The same trend was visible in the ongoing prescriptions at admission revealing a similar out-of-hospital approach. This suggests a change in sedative prescribing strategy rather than the choice of alternative, non-pharmacological approaches. Furthermore, the variation between similar services of different hospitals points out the consequences of local prescribing cultures and the importance of continuously monitoring and benchmarking medication prescriptions.

References

  1. Gardner DM, Baldessarini RJ, Waraich P. Modern antipsychotic drugs: a critical overview. CMAJ. 2005 Jun;172(13):1703–11.
  2. FDA. (2016). Atypical Antipsychotic Drugs Information.
  3. Krutika Chokhawala LS. (2022). Antipsychotic Medications.
  4. Swissmedicinfo. (2021). Quietapin-Mepha. https://www.swissmedicinfo.ch/ViewMonographie?isNewUpdate=1
  5. Gaertner J, Eychmueller S, Leyhe T, Bueche D, Savaskan E, Schlögl M. Benzodiazepines and/or neuroleptics for the treatment of delirium in palliative care?-a critical appraisal of recent randomized controlled trials. Ann Palliat Med. 2019 Sep;8(4):504–15.
  6. Højlund M, Andersen JH, Andersen K, Correll CU, Hallas J. Use of antipsychotics in Denmark 1997-2018: a nation-wide drug utilisation study with focus on off-label use and associated diagnoses. Epidemiol Psychiatr Sci. 2021 Apr;30:e28.
  7. Alexander GC, Gallagher SA, Mascola A, Moloney RM, Stafford RS. Increasing off-label use of antipsychotic medications in the United States, 1995-2008. Pharmacoepidemiol Drug Saf. 2011 Feb;20(2):177–84.
  8. Walsh JK. Drugs used to treat insomnia in 2002: regulatory-based rather than evidence-based medicine. Sleep. 2004 Dec;27(8):1441–2.
  9. Reus VI, Fochtmann LJ, Eyler AE, Hilty DM, Horvitz-Lennon M, Jibson MD, et al. The American Psychiatric Association Practice Guideline on the Use of Antipsychotics to Treat Agitation or Psychosis in Patients With Dementia. Am J Psychiatry. 2016 May;173(5):543–6.
  10. Gareri P, Segura-García C, Manfredi VG, Bruni A, Ciambrone P, Cerminara G, et al. Use of atypical antipsychotics in the elderly: a clinical review. Clin Interv Aging. 2014 Aug;9:1363–73.
  11. Oh ES, Fong TG, Hshieh TT, Inouye SK. Delirium in Older Persons: Advances in Diagnosis and Treatment. JAMA. 2017 Sep;318(12):1161–74.
  12. Nikooie R, Neufeld KJ, Oh ES, Wilson LM, Zhang A, Robinson KA, et al. Antipsychotics for Treating Delirium in Hospitalized Adults: A Systematic Review. Ann Intern Med. 2019 Oct;171(7):485–95.
  13. FDA. (2023). Drug Alerts and Statements.
  14. Yunusa I, Rashid N, Demos GN, Mahadik BS, Abler VC, Rajagopalan K. Comparative Outcomes of Commonly Used Off-Label Atypical Antipsychotics in the Treatment of Dementia-Related Psychosis: A Network Meta-analysis. Adv Ther. 2022 May;39(5):1993–2008.
  15. Stogios N, Smith E, Bowden S, Tran V, Asgariroozbehani R, McIntyre WB, et al. Metabolic adverse effects of off-label use of second-generation antipsychotics in the adult population: a systematic review and meta-analysis. Neuropsychopharmacology. 2022 Feb;47(3):664–72.
  16. Yunusa I, Alsumali A, Garba AE, Regestein QR, Eguale T. Assessment of Reported Comparative Effectiveness and Safety of Atypical Antipsychotics in the Treatment of Behavioral and Psychological Symptoms of Dementia: A Network Meta-analysis. JAMA Netw Open. 2019 Mar;2(3):e190828.
  17. Dementia: Assessment, management and support for people living with dementia and their carers. London: National Institute for Health and Care Excellence (NICE); 2018 Jun.
  18. England LCNN. Appropriate prescribing of antipsychotic medication in dementia. 2022.
  19. Jahnsen JA, Widnes SF, Schjøtt J. Quetiapine, Misuse and Dependency: A Case-Series of Questions to a Norwegian Network of Drug Information Centers. Drug Healthc Patient Saf. 2021 Jul;13:151–7.
  20. Corbett A, Burns A and Ballard C. Don't use antipsychotics routinely to treat agitation and aggression in people with dementia. Bmj. 2014; 349(nov03 1):g6420-g6420.
  21. Hálfdánarson Ó, Zoëga H, Aagaard L, Bernardo M, Brandt L, Fusté AC, et al. International trends in antipsychotic use: A study in 16 countries, 2005-2014. Eur Neuropsychopharmacol. 2017 Oct;27(10):1064–76.
  22. Nishtala PS, Chyou TY. An Updated Analysis of Psychotropic Medicine Utilisation in Older People in New Zealand from 2005 to 2019. Drugs Aging. 2022 Aug;39(8):657–69.
  23. Kelleher JE, Weedle P, Donovan MD. The Prevalence of and Documented Indications for Antipsychotic Prescribing in Irish Nursing Homes. Pharmacy (Basel). 2021 Sep;9(4):160.
  24. Tumusiime WA, Hardman CJ, Breen JL. Antipsychotic prescribing in people admitted to hospital with dementia or delirium. Australas J Ageing. 2022 Jun;41(2):258–64.
  25. Assurance H. (2018). Helsana-Arzneimittelreport. Available at: file:///C:/Users/susan/Downloads/arzneimittelreport-2018.pdf
  26. Assurance H. Helsana-Arzneimittelreport. 2020. Available at: https://www.helsana.ch/de/helsana-gruppe/medien-publikationen/mitteilungen/arzneimittelreport-2020.html
  27. Smarter Medicine CwS. SmarterMedicine_Flyer_ENG_web300. 2016. Available at https://www.smartermedicine.ch/fileadmin/user_upload/Adaptionen/smartermedicine/Dokumente/Listen_Flyer_neu/SmarterMedicine_Flyer_ENG_web300.pdf
  28. Del Giorno R CA, Gabutti L. Benzodiazépines chez les patients âgés : le côté sombre d’une pilule magique [Benzodiazepines in elderly patients : the dark side of a magic pill]. 2017;13(547):282-84.
  29. Del Giorno R, Greco A, Zasa A, Clivio L, Pironi M, Ceschi A, et al. Combining prescription monitoring, benchmarking, and educational interventions to reduce benzodiazepine prescriptions among internal medicine inpatients; a multicenter before and after study in a network of Swiss Public Hospitals. Postgrad Med. 2018 Sep;130(7):627–36.
  30. Del Giorno R, Ottini A, Greco A, Stefanelli K, Kola F, Clivio L, et al. Peer-pressure and overuse: the effect of a multimodal approach on variation in benzodiazepine prescriptions in a network of public hospitals. Int J Clin Pract. 2020 Mar;74(3):e13448.
  31. Del Giorno R, Schneiders C, Stefanelli K, Ceschi A, Gyoerik-Lora S, Aletto I, et al. Unexpected Increase in Benzodiazepine Prescriptions Related to the Introduction of an Electronic Prescribing Tool: Evidence from Multicenter Hospital Data. Diagnostics (Basel). 2019 Nov;9(4):190.
  32. Del Giorno R, Ceschi A, Pironi M, Zasa A, Greco A, Gabutti L. Multifaceted intervention to curb in-hospital over-prescription of proton pump inhibitors: A longitudinal multicenter quasi-experimental before-and-after study. Eur J Intern Med. 2018 Apr;50:52–9.
  33. Erard Y, Del Giorno R, Zasa A, De Gottardi S, Della Bruna R, Keller F, et al. A multi-level strategy for a long lasting reduction in unnecessary laboratory testing: A multicenter before and after study in a teaching hospital network. Int J Clin Pract. 2018 Oct;73(3):e13286.
  34. Moreno C, Wykes T, Galderisi S, Nordentoft M, Crossley N, Jones N, et al. How mental health care should change as a consequence of the COVID-19 pandemic. Lancet Psychiatry. 2020 Sep;7(9):813–24.
  35. von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP; STROBE Initiative. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. BMJ. 2007 Oct;335(7624):806–8.
  36. Kofam. (2023). Koordinationsstelle Forschung am Menschen. Available at: https://kofam.ch/de
  37. Cumby RE, Huizinga J. Testing the Autocorrelation Structure of Disturbances in Ordinary Least-Squares and Instrumental Variables Regressions. Econometrica. 1992;60(1):185–95.
  38. Smarter Medicine CwS. (2023). Liste «Top 5» Médecine Interne Générale hospitalière. Available at : https://www.smartermedicine.ch/fr/liste-top-5/medecine-interne-generale-hospitaliere-2023
  39. cantonale T-Udm. Situazione epidemiologica in Ticino. 2023. Available at: https://www4.ti.ch/dss/dsp/covid19/popolazione/situazione-epidemiologica
  40. Morgan SG, Weymann D, Pratt B, Smolina K, Gladstone EJ, Raymond C, et al. Sex differences in the risk of receiving potentially inappropriate prescriptions among older adults. Age Ageing. 2016 Jul;45(4):535–42.
  41. Resnick B, Boltz M, Galik E, Kuzmik A, McPherson R, Drazich B, et al. Differences in Medication Use by Gender and Race in Hospitalized Persons Living with Dementia. J Racial Ethn Health Disparities. 2024 Oct;11(5):2839–47. 10.1007/s40615-023-01745-9
  42. Waring JJ. A qualitative study of the intra-hospital variations in incident reporting. Int J Qual Health Care. 2004 Oct;16(5):347–52.
  43. Sandora TJ, Fung M, Melvin P, Graham DA, Rangel SJ. National Variability and Appropriateness of Surgical Antibiotic Prophylaxis in US Children’s Hospitals. JAMA Pediatr. 2016 Jun;170(6):570–6.
  44. Sanchez Traun KB, Schauberger CW, Ramirez LD, Jones CW, Lindberg AF, Molero Bravo RA, et al. Opioid prescribing trends in postpartum women: a multicenter study. Am J Obstet Gynecol MFM. 2019 Nov;1(4):100055.
  45. Rogers MA, Blumberg N, Saint S, Langa KM, Nallamothu BK. Hospital variation in transfusion and infection after cardiac surgery: a cohort study. BMC Med. 2009 Jul;7(1):37.
  46. McLeod M, Ahmed Z, Barber N, Franklin BD. A national survey of inpatient medication systems in English NHS hospitals. BMC Health Serv Res. 2014 Feb;14(1):93.
  47. Lelong A, Léger S, Vendittelli F, Blanquet M, Thuong CT, Belgacem B, et al. A quality indicator can be biased by intra-hospital heterogeneity: the case for quality of patient record keeping in France. Eur J Public Health. 2015 Oct;25(5):787–91.
  48. Hudelson P, Vilpert S. Overcoming language barriers with foreign-language speaking patients: a survey to investigate intra-hospital variation in attitudes and practices. BMC Health Serv Res. 2009 Oct;9(1):187.